Ventavis To Cost $65,000 - $100,000 Per Year, CoTherix Says

The PAH therapy is competitively priced against United Therapeutics' Remodulin and Actelion's Tracleer, CoTherix says. With its sales force still in training, Ventavis has launched ahead of schedule.